Online inquiry

IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15040MR)

This product GTTS-WQ15040MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Cancers, Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15040MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15864MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ10261MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ4754MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ6493MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ5394MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ4473MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ992MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ12316MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MT203
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW